Loading…
CRDL
Cardiol Therapeutics Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 14161Y200
$1.94-5.83%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $226.64M
- P/E
- —
- Forward P/E
- —
- P/B
- 13.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.23
- ROE
- -190.18%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.47
- 52-week high
- $2.28
- 52-week low
- $0.88
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -52.8% over 5Y.
today you would have $412.05▼ -58.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $0.95 | $1.28 | $0.84 | $0.51 | |
| P/B | 3.1x | 5.3x | 4.3x | 2.0x | 0.6x |
| EPS | -$0.39 | -$0.51 | -$0.44 | -$0.49 | |
| ROE | -123.95% | -189.17% | -148.32% | -99.58% | -59.25% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALECAlector, Inc. | $2.02 | — | — | — | -385.11% | $225.55M |
| SLGLSol-Gel Technologies Ltd. | $68.81 | — | 4.7x | — | -40.85% | $225.28M |
| AMWLAmerican Well Corp | $13.21 | — | 1.0x | — | -29.12% | $224.69M |
| AVXLAnavex Life Sciences Corp | $2.47 |
About the company
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
- 18
- Oakville, Canada
Company description provided by Yahoo Finance.